Novartis, Watson End Suit Over Enablex ANDA
Novartis Pharmaceuticals Corp. has dropped its suit against Watson Pharmaceuticals Inc. over the generic-drug maker's plans to manufacture a version of Enablex, a treatment for overactive bladder syndrome....To view the full article, register now.
Already a subscriber? Click here to view full article